Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

• Status: Active, not recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with carboplatin and/or Paclitaxel chemotherapy

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Olaparib; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors

Criteria

Inclusion Criteria:

• Male or female patients with a histologically or cytologically diagnosed malignant solid tumour

• Adequate bone marrow, hepatic and renal function

• Performance status of no more than 2 ( ECOG scale).

Exclusion Criteria:

• Any chemotherapy, radiotherapy ( except palliative), endocrine or immunotherapy within 4 weeks prior to entry

• Major surgery with 4 weeks of entering the study and must have recovered from effects of the major surgery

• More than two previous courses of platinum-containing chemotherapy

• Heavily pre-treated patients(> 2 courses of previous chemotherapy and/or extensive irradiation leading to bone marrow deficiency) will be excluded from the study